AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01154894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aravita including arachidonic acid and docosaheaenoic acid
Description: Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
Study NCT01850082 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vein Harvesting Procedures
Description: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
Study NCT04879316 — intervention group
Intervention type: OTHER
Intervention: Resting Energy Expenditure measurement
Description: Resting Energy Expenditure measurement using indirect calorimetry
Study NCT00641758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pycnogenol
Description: Pycnogenol 100mg twice daily
Study NCT00641758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100mg twice daily
Study NCT04453215 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: GaAlAs semiconductor diode laser device
Description: low-level laser therapy
Study NCT04453215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs semiconductor diode laser device
Description: low-level laser therapy
Study NCT01356667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DARTNA
Description: 3-hour protocol provided 2x/week over 12 weeks
Study NCT01356667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-As-Usual
Description: Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
Study NCT01317290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 PUFA free olive oil
Description: negative control
Study NCT01317290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: linseed oil
Study NCT04107896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Cap silodosin
Study NCT04107896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Cap tamsulosin
Study NCT01564745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional respiratory evaluation
Description: Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
Study NCT04903834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Soton hyperinflammation score
Description: Score for hyperinflammation defined by blood parameters and other physiological measurements
Study NCT04903834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HScore
Description: Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications
Study NCT03344822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: radioactive tracer for PET-CT (68Ga-PSMA-11)
Study NCT03344822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Choline PET-CT
Description: radioactive tracer for PET-CT (18F-Choline PET-CT)
Study NCT04652141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AsthmaTuner
Description: AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
Study NCT00747318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKP FlutiForm HFA pMDI
Description: Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
Study NCT02841267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 06252616
Study NCT02107248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep position: no restrictions
Description: during the first eight weeks after total hip replacement following a posterolateral surgical approach
Study NCT02107248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep position: supine
Description: during the first eight weeks after total hip replacement following a posterolateral surgical approach
Study NCT01468532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT01468532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pasireotide
Description: Given IM
Study NCT01468532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT03857412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular polishing
Description: Capsular polishing taking place during cataract surgery
Study NCT03857412 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non capsular polishing
Description: No capsular polishing taking place during cataract surgery
Study NCT02572843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (anti-PD-L1)
Description: fixed dosing 750 mg
Study NCT02161861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cFFE increase the fusiogenic capacities of a gamete
Study NCT00412035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A injection
Description: 10 units per kilo to maximum of 400 units
Study NCT00412035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: 10 units per kilo to maximum of 400 units
Study NCT03044262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid) that is part of an ostomy device
Study NCT03044262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed adhesive strip that in the future might be part of an ostomy device
Study NCT00853281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hammocks with LLIN
Description: Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
Study NCT00853281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard vector control measures
Description: Insectice-treated net
Study NCT03791385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Description: A communication system frequently used with non-verbal children with autism spectrum disorders (ASD) that uses a series of pictures that describe how a certain activity is done, in our case showing a structured method and technique for teeth brushing.
Study NCT03806868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: voucher for ordering foods (ONLY omega-3 rich foods)
Description: A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
Study NCT03806868 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: voucher for ordering foods in general (any type of foods)
Description: A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
Study NCT00914290 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX056
Description: IPX056 ER capsule containing 10 mg baclofen
Study NCT00914290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPX056
Description: IPX056 ER capsule containing 10 mg baclofen
Study NCT00914290 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baclofen IR
Description: Encapsulated baclofen tablet 5 mg per capsule
Study NCT00914290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen IR
Description: Encapsulated baclofen tablet 5 mg per capsule
Study NCT00914290 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056
Description: Placebo capsule for IPX056
Study NCT00914290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IPX056
Description: Placebo capsule for IPX056
Study NCT00914290 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IR
Description: Placebo encapsulated baclofen placebo tablet
Study NCT00914290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IR
Description: Placebo encapsulated baclofen placebo tablet
Study NCT02380508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: Intradermal injection
Study NCT02380508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No vaccination
Study NCT02380508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Sii
Description: intradermal injection
Study NCT02146222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR/PDGFR dual kinase inhibitor X-82
Description: Given PO
Study NCT02146222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT02146222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorothymidine
Description: Undergo FLT PET/CT
Study NCT02146222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo FLT PET/CT
Study NCT02146222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02146222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01548859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
Study NCT01548859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: end tidal concentration of % 0,5-8
Study NCT02223754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B
Description: Soft contact lens to be worn as daily wear, monthly replacement modality.
Study NCT02223754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Soft contact lens to be worn as daily wear, monthly replacement modality.
Study NCT02223754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Soft contact lens to be worn as daily wear, daily disposable modality.
Study NCT02836236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF 25 mg tablet administered orally once daily
Study NCT02223754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Soft contact lens to be worn as daily wear, daily disposable modality.
Study NCT01177839 — intervention group
Intervention type: OTHER
Intervention: Screening sheets
Description: Reviewing screening sheets
Study NCT02906202 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LentiGlobin BB305 Drug Product
Description: LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Study NCT02169037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM Ablation
Description: Substrate ablation for AF, via ablation of rotors and focal sources alone.
Study NCT02836236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: TDF 300 mg tablet administered orally once daily
Study NCT02836236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: TAF placebo tablet administered orally once daily
Study NCT02169037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional AF ablation with PVI
Description: Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
Study NCT03930134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sparse uterine suture
Description: The slowly absorbed Vicryl 1 suture with a large round needle is introduced intramyometrially right above the endometrium. The suture starts in one corner and proceeds along the lower then the upper edge returning back to the incision point. Subserous layer is closed upon using the same thread in order to cover the purse suture and to complete the haemostasis while increasing the wound thickness.
Study NCT03930134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: one layer uterine closure
Description: one layer classical continious uterine closure using slowly absorbed Vicryl 1
Study NCT02836236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: TDF placebo tablet administered orally once daily
Study NCT01608243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLIT tablets of house dust mite allergen extracts
Description: 10 dosing days
Study NCT01608243 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: 10 dosing days
Study NCT04186806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray
Description: 20 ml bottle
Study NCT04186806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray
Description: 20 ml bottle
Study NCT04186806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray
Description: 44.3 ml bottle
Study NCT04186806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray
Description: 44.3 ml bottle
Study NCT04323306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product
Study NCT03596281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Q3W IV
Study NCT02285595 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sonendo GentleWave™ System
Study NCT00210522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ 333369
Description: Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
Study NCT01252121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systane Ultra Lubricant Eye Drops
Description: One drop in study eye, one time, during office visit.
Study NCT01252121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hialid 0.1 Artificial Tears Eye Drops
Description: One drop in study eye, one time, during office visit.
Study NCT01252121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Unisol 4 Saline Solution
Description: One drop in study eye, one time, during office visit.
Study NCT03933332 — intervention group
Intervention type: OTHER
Intervention: Diaphragm thickness
Description: measured at apposition zone using ultrasonography in mm
Study NCT03933332 — intervention group
Intervention type: OTHER
Intervention: Cross-sectional area of rectus femoris muscle
Description: measured at lower one-third line between Spina iliaca anterior inferior (SIAI) and upper border femur patella using ultrasonography in cm\^2
Study NCT03933332 — intervention group
Intervention type: OTHER
Intervention: Cross-sectional area of biceps brachii
Description: measured at biceps brachii muscle using ultrasonography in cm\^2
Study NCT03933332 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C-Reactive Protein (CRP) Level
Description: quantitative CRP using ELISA method in mcg/mL
Study NCT04109742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphatidylcholine-curcumin complex supplement
Description: a dietary curcumin supplement given at two different doses
Study NCT04109742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo curcumin capsule
Description: matching placebo to active curcumin capsules
Study NCT03958240 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples, tumor biopsy specimens and ascites samples will be collected.
Description: Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice) for a maximum follow-up period of 5 years from baseline:~* at Baseline.~* at every surgical procedure or tumor biopsy.~* every 6 months (± 2 months) (only blood sample).~* at the time of the progression or recurrence, additional samples will be collected, and optionally at the time of the following progressions or recurrences (if applicable).~For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks).
Study NCT01080651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
Study NCT03444935 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Follow-up phone call
Description: Please see arm/group description.
Study NCT03444935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up phone call
Description: Please see arm/group description.
Study NCT03929926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: receive usual care
Study NCT03929926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Educational Materials
Description: Receive educational materials via mail
Study NCT03929926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive shared decision making and lung cancer screening information
Study NCT03929926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo decision counseling session
Study NCT01493960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobitolimod
Description: 30 mg rectal dose at week 0 and 4
Study NCT01493960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal dose at week 0 and 4
Study NCT02215330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study NCT02215330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT00345813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: Given orally
Study NCT00345813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein isolate
Description: Given orally
Study NCT00345813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00602186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsolusin
Description: 0.4 mg /day
Study NCT00602186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin
Description: 1 mg/day
Study NCT01266447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT01266447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01266447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT01266447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT01266447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT00674115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/sodium bicarbonate
Description: Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
Study NCT00674115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole magnesium
Description: Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
Study NCT00674115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: Sodium bicarbonate. Single dose.
Study NCT01516203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.